Expert Interview
Discussing the ongoing Karyopharm Therapeutics' SENTRY trial Evaluating Selinexor in Combination with Ruxolitinib in JAKi-Naive Myelofibrosis patients
Ticker(s): KPTI, INCYInstitution: Mount Sinai
- Assistant Professor at the Mount Sinai Health System (Icahn School of Medicine).
- Manages 40-50 patients with MF currently and is familiar with the MOMENTUM trial.
- Research interests include myeloproliferative neoplasms, especially polycythemia vera and myelofibrosis, as well as acute myeloid leukemia, hemophagocytic lymphohistiocytosis, systemic mastocytosis, and chronic myelomonocytic leukemia and has published extensively on these topics.
Do yo have any high level thoughts on XPO1 inhibition to treat myelofibrosis?
Added By: wilson_adminDo you have any concerns about potential AEs from selinexor?
Added By: wilson_adminWhat would SENTRY need to show from selinexor to justify using in combination instead of just using a monotherapy JAKi?
Added By: wilson_admin1) How much can TSS be reduced with selinexor beyond ruxolitinib?
2) What delta do you forecast?
Do you believe it's possible the study will hit on both SVR35 and TSS? If it hits SVR but misses TSS, what do you believe are the clinical implications?
Added By: user69a5ecf8Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
